Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alcon gets Japanese Patanol OK
Patanol solution provides both mast cell stabilizing and anti-histamine properties in a single molecule, providing patients with rapid, effective and lasting relief from the signs and symptoms of
Patanol solution provides both mast cell stabilizing and anti-histamine properties in a single molecule, providing patients with rapid, effective and lasting relief from the signs and symptoms of
According to the study data, there were no meaningful signals of carcinogenicity detected after two years of testing in two species – rats and mice. The company said
The American Lung Association will expand its annual influenza awareness efforts to educate the public about influenza and the need for vaccination through support and resources from Sanofi
In vitro toxicogenomics offers the potential for companies to reduce the attrition rate of compounds due to safety problems in the later stages of drug development, when those
The special protocol assessment (SPA) documents the FDA’s agreement regarding the trial’s design and planned analyses to fulfill commitments that may be required under provisions relating to accelerated
The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition
In a single center, randomized, placebo-controlled study of 76 smokers, patients in the nalmefene 40mg group demonstrated numerically higher abstinence rates at all timepoints relative to placebo. Patients
Genzyme said that it will conduct the study in patients with type 1 Gaucher disease at medical centers in Europe, Israel, South America and the US. The open-label
The study is designed to determine if the addition of a radiopharmaceutical to bisphosphonates for patients with asymptomatic or stable symptomatic bone metastasis will delay the time to
The company expects to initiate two phase II studies within the next six months. The trials will have the goal of confirming the mechanism of action of NCX